Tuberculosis Theraphy

Advocates and affected communities working towards the global scale-up of a short-course TB preventive therapy have hailed the recent announcement of the launch of what they say is a decently priced, patient-friendly fixed-dose combinations of FDC 3HP in five high burden HIV and TB countries. The news, made possible by a Unitaid-funded project comes at a time as communities grapple with the devastation wrought by the COVID-19 pandemic. To discuss this further, Tracey Boomgaard spoke to Lynette Mabote, Advocacy advisor with the Treatment Action Group ….